Tandem Diabetes Care
TNDM Small CapHealthcare · Medical Devices
Mis à jour: Aug 2, 2026, 22:14 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Tandem Diabetes Care en bref
Tandem Diabetes Care (TNDM) is currently trading at 16,91 € with a market capitalization of 1,2 Md €. The 52-week range spans from 8,65 € to 25,71 €; the current price is 34.2% below the yearly high. Year-over-year revenue growth stands at +5.5%.
💰 Dividende
Tandem Diabetes Care currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
20 analystes évaluent Tandem Diabetes Care (TNDM) au consensus : Acheter. L'objectif de cours moyen est de 24,73 €, soit un potentiel de +46.28% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 13,44 € à 43,35 €.
Tandem Diabetes Care : la thèse d'investissement en détail
Tandem Diabetes Care (TNDM) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Wall Street consensus sits at Buy with an average price target implying roughly 46.28% upside from current levels — analyst sentiment is firmly constructive.
Le scénario baissier
Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. The debt-to-equity ratio of 554.92% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn. Short interest sits at 25.76% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.
À surveiller
- The analyst consensus price target implies 46.28% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Thèse d'investissement : forces et faiblesses
- Marge brute élevée de 54.93% — signe d'un pouvoir de fixation des prix
- Consensus des analystes : Buy
- –Actuellement non rentable
- –Endettement élevé (D/E 554.92)
- –Positions vendeuses élevées (25.76%)
- –Free cash flow négatif
Aperçu technique
The price is in a transition zone relative to the moving averages — no clear signal.
Profil de risque
The data points to above-average price swings, elevated short interest (25.76%), higher leverage relative to equity.
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Tandem Diabetes Care?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Plutôt un fonds qu’une action isolée ? Comparatif d’ETF :
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news